Physician profile
Armand B Cognetta
NPI 1003922592
$138,546.80
in general payments reported to CMS, 2019-2025
8 companies · $38K in 2025
The $38K reported for 2025 was more than what 98% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,204 · 2020: $6,799 · 2021: $22K · 2022: $8,847 · 2023: $20K · 2024: $38K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Grant: $15K · Travel and Lodging: $2,658 · Food and Beverage: $1,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,493.75 |
| Grant | $15,089.10 |
| Travel and Lodging | $2,658.01 |
| Food and Beverage | $1,429.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $105,334.53 | 2019-2025 | Libtayo |
| Biofrontera INC. | $15,111.12 | 2025 | Rhodoled Xl, Ameluz |
| Genzyme Corporation | $13,917.61 | 2020-2021 | |
| Sensus Healthcare, INC. | $2,500.00 | 2019 | |
| Dusa Pharmaceuticals, INC. | $1,600.00 | 2019 | |
| Organogenesis INC. | $43.21 | 2025 | Apligraf |
| Allergan, INC. | $26.10 | 2021 | |
| Genentech USA, INC. | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$684,365.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armand Cognetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.